Casa Sollievo Della Sofferenza
- Address
- lock Available on a paid plan
Oncology and Hematologic Malignancies
At Casa Sollievo Della Sofferenza, a major share of research in Neoplasms and Hemic and Lymphatic Diseases focuses on cancers such as multiple myeloma, diffuse large B-cell lymphoma, acute leukemias, and melanoma. These studies are designed to test new treatment combinations, improve disease control, and refine strategies for patients with relapsed, refractory, or newly diagnosed cancer.
- Blood cancers including multiple myeloma, lymphoma, and acute lymphoblastic leukemia
- Solid tumors such as colorectal cancer, gastric cancer, and pancreatic cancer
- Melanoma and other advanced malignancies
The research portfolio includes trials evaluating innovative immunotherapies, targeted therapies, and combination approaches aimed at improving survival and reducing relapse.
Gastroenterology and Liver Disease
The site has a strong program in Digestive System Diseases and Nutritional and Metabolic Diseases, with trials in Crohn’s disease, ulcerative colitis, inflammatory bowel disease, NASH, and primary biliary cholangitis. Research here is centered on better control of inflammation, improved healing of the bowel, and therapies that may slow or reverse liver damage.
- Crohn’s disease and ulcerative colitis
- NASH, MASH, and other chronic liver disorders
- Studies aiming to improve symptom control, tissue healing, and long-term outcomes
Several trials are testing new biologic and metabolic therapies to help patients achieve deeper and more durable remission.
Kidney and Metabolic Research
Clinical trials in Cardiovascular Diseases, Immune System Diseases, and Nutritional and Metabolic Diseaseschronic kidney disease, IgA nephropathy, hypertension, and kidney complications in type 2 diabetes. These studies are evaluating whether new or combined treatments can better protect kidney function and reduce disease progression.
- Chronic kidney disease and IgA nephropathy
- Kidney disease linked to diabetes and hypertension
- Trials focused on slowing decline in renal function and improving proteinuria control
The research also includes efforts to improve treatment choices based on biopsy findings and to evaluate therapies that may lower inflammation and cardiovascular risk.
Autoimmune and Inflammatory Disorders
A substantial part of the program addresses Immune System Diseases and Skin and Connective Tissue Diseases, with studies in myasthenia gravis, graft-versus-host disease, juvenile psoriatic arthritis, and other immune-mediated conditions. The goal is to test treatments that can calm abnormal immune activity while improving quality of life.
- Generalized myasthenia gravis
- Chronic and acute graft-versus-host disease
- Juvenile psoriatic arthritis and related inflammatory conditions
These trials often compare new biologic medicines with existing care to see whether they can provide better symptom relief and longer-lasting disease control.
Neurology and Rare Diseases
Research in Nervous System Diseases and Congenital, Hereditary, and Neonatal Diseases and Abnormalities includes studies of epilepsy, Huntington’s disease, amyotrophic lateral sclerosis, and hypophosphatasia. These trials are aimed at understanding disease mechanisms and testing therapies for conditions with limited treatment options.
- Focal epilepsy and refractory partial onset epilepsy
- Huntington’s disease and amyotrophic lateral sclerosis
- Hypophosphatasia and other rare inherited disorders
The research focus is on improving neurological function, reducing symptoms, and exploring new options for rare diseases that need more effective therapies.
Pediatric Oncology and Specialized Cancers
Casa Sollievo Della Sofferenza also contributes to pediatric and adolescent oncology research within Neoplasms and Diseases of the Hemic and Lymphatic System. Trials include high-risk neuroblastoma, acute lymphoblastic leukemia, and lymphoblastic lymphoma, with a focus on improving cure rates and reducing relapse in younger patients.
- High-risk neuroblastoma
- Childhood and adolescent acute lymphoblastic leukemia
- Lymphoblastic lymphoma and related rare pediatric cancers
These studies are designed to refine treatment effectiveness while supporting safer and more durable long-term outcomes for children and adolescents.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 238 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 223 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 60 by active trials.
- 1Janssen Cilag International4active
lock +59 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International14trials
lock +26 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Casa Sollievo Della Sofferenza
lock Showing 1 of 151 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 40-Week Randomized Study Evaluating the Efficacy and Safety of Weekly Insulin Icodec/Semaglutide Versus Daily Insulin Glargine in Type 2 Diabetes Patients | Novo Nordisk A/S | Phase III | Not Recruiting | Feb 2024 | Jun 2025 |
IMP list
lock Showing 1 of 238 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 14 | Unknown | 2021-02-16 | 2026-07-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.